PKO Investment Management Joint Stock Co Boosts Stock Position in IQVIA Holdings Inc. $IQV

PKO Investment Management Joint Stock Co increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.3% in the second quarter, HoldingsChannel reports. The firm owned 8,000 shares of the medical research company’s stock after acquiring an additional 1,000 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in IQVIA were worth $1,261,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the last quarter. Golden State Wealth Management LLC lifted its stake in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in IQVIA in the 1st quarter valued at about $33,000. Trust Co. of Toledo NA OH acquired a new stake in IQVIA in the 2nd quarter valued at about $39,000. Finally, J.Safra Asset Management Corp increased its holdings in shares of IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 169 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Truist Financial upped their price objective on IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. UBS Group upped their price objective on IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $234.57.

IQVIA Stock Up 0.3%

IQV opened at $220.64 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $225.91. The stock has a market cap of $37.51 billion, a P/E ratio of 31.93, a P/E/G ratio of 2.42 and a beta of 1.32. The stock’s 50 day moving average price is $194.47 and its 200 day moving average price is $171.27. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company posted $2.64 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.